LONDON/FRANKFURT May 22 Private equity group
Bridgepoint has picked Morgan Stanley to sell
Aenova, hoping to pull in more than 400 million euros ($510
million) for the German vitamins and generic prescription drugs
maker, two people familiar with the situation said.
The auction of Aenova is planned to kick off in the autumn,
the people said, and is expected to attract rival vitamin makers
such as German chemicals group BASF and Dutch
supplements maker DSM, as well as private equity
Bridgepoint was unavailable for comment. Aenova and Morgan
Stanley declined to comment.